Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe


Por: Noguera-Julian A, Buonsenso D, Mckenna L, Seddon JA and Ritz N

Publicada: 1 sep 2021 Ahead of Print: 1 oct 2021
Categoría: Medicine (miscellaneous)

Resumen:


Filiaciones:
Noguera-Julian A:
 Translational Research Network in Pediatric Infectious Diseases (RITIP), Madrid, Spain

 Center for Biomedical Network Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain

 Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Infectious Diseases Unit, Department of Pediatrics, Sant Joan de Déu Hospital Research Foundation, Barcelona, Spain

 Both authors share credit for 1st authorship

 Department of Pediatrics, University of Barcelona, Barcelona, Spain

Buonsenso D:
 Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Ital

 Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy

 Center for Global Health Research and Studies, Università Cattolica del Sacro Cuore, Rome, Italy

 Both authors share credit for 1st authorship

Mckenna L:
 Treatment Action Group, New York, USA

Seddon JA:
 Department of Infectious Diseases, Imperial College, London, UK

 Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa

Ritz N:
 Infectious Diseases Unit and Migrant Health Service, University Children's Hospital Basel, University of Basel, Basel, Switzerland

 Department of Biomedicine, University of Basel, Basel, Switzerland

 Department of Paediatrics, The University of Melbourne, Parkville, Australia
ISSN: 09031936





EUROPEAN RESPIRATORY JOURNAL
Editorial
EUROPEAN RESPIRATORY SOC JOURNALS LTD, 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND, Suiza
Tipo de documento: Letter
Volumen: 58 Número: 3
Páginas: 2101196
WOS Id: 000731853700026
ID de PubMed: 34049946
imagen Bronze

MÉTRICAS